Intellia Therapeutics Inc
NTLA
ISIN US45826J1051 / Valor 32256913
Intellia Therapeutics Inc
UMushroom community rating:
About company
Intellia Therapeutics Inc is a biotechnology company focused on developing curative genome editing treatments using CRISPR/Cas9 technology. Founded with the mission to transform the lives of people with severe diseases, Intellia collaborates with partners like Regeneron to explore in vivo applications of genome editing. The company's work in harnessing the potential of CRISPR to make specific changes in the DNA of humans, animals, and plants has captured global attention for its potential to revolutionize disease treatment. Led by co-founder Jennifer Doudna, Intellia is at the forefront of the genome editing field, working towards developing innovative therapies for a range of genetic disorders.
Summarized from source with an LLMView SourceSector: TechnologyKey figures
Performance
Volatility
2291 M
Market cap (USD)
734,845
Daily traded volume (Shares)
23.75 / 22.27
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
